Curated content that matters
Explore stories across diverse categories
HD Korea Shipbuilding & Offshore Engineering (KSOE) has demonstrated its differentiated competitiveness in the gas carrier market. Leveraging
Kia will start mass-producing its compact electric sports utility vehicle (SUV), the EV2, in Europe next year. The
Kia is reducing the price of the 2026 EV9 by up to $2,000 in the U.S., aiming to
Stablecoin transactions in South Korea reached $41.3 billion in the first quarter of 2025, driven largely by Tether
(Photo=HomePlus) Several South Korean food companies have suspended product deliveries to Homeplus, a major local retail chain currently undergoing court-led corporate restructuring. Binggrae, a leading Korean dairy and snack manufacturer, halted deliveries to Homeplus on May 24, citing unresolved negotiations over contract terms. This marks Binggrae's first such suspension, even though the company had continued supplies when Homeplus initially filed
(Photo=Pixabay) South Korea will freeze raw milk prices again this year, marking the second year in a row without a price change. On May 27, the Korea Dairy Committee-a group comprising dairy farmers and milk processors-announced there would be no negotiations in 2025. The decision was based on the fact that production costs rose only 1.5% last year, below the
(Photo=TVING, Coupang Play, Motionelements) The competition among domestic companies to secure the No. 2 spot in Korea’s online video service (OTT) market is heating up. While global giant Netflix leads the pack, the combined influence of local platforms like TVING, Coupang Play, and Wavve is not far behind. Some predict that if the merger between TVING and Wavve goes through,
(Photo=CU) CU, one of South Korea’s largest convenience store brands, is making its U.S. debut with its first store set to open in Hawaii this October, marking the first-ever entry of a Korean convenience store chain into the American market. On May 27, CU’s operator BGF Retail announced the establishment of a local subsidiary in Hawaii and the signing of
(Photo=Samsung Biologics) Samsung Biologics, a South Korea–based biopharmaceutical contract development and manufacturing organization (CDMO), has secured new contracts worth a combined $319 million with pharmaceutical companies in Europe and Asia, pushing its total orders this year past $2.19 billion, the company announced on May 26. The two latest deals—valued at $175 million and $144 million, respectively—cover contract manufacturing services through
